UNSPSC 51292917: Clomipramine hydrochloride

This classification denotes a tricyclic antidepressant with the molecular formula C19H23ClN2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2LXW0L6GWJ, chemically known as 5h-dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-n,n-dimethyl-, monohydrochloride but more generally known as clomipramine hydrochloride, which bears US NIH Compound Identifier 68539. European Medicines Agency schedules Clomipramine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01361MIG.

UNSPSC 51292917 Clomipramine hydrochloride is a Commodity code that nominally identifies a single pharmaceutical product, but recent state and local procurement activity under this code does not target clomipramine specifically. Instead, issuing bodies are soliciting pharmaceutical procurement and pharmacy benefit management services at a much broader scope — including generic multi-source pharmaceuticals, over-the-counter products, naloxone and drug deactivation systems, and direct-to-manufacturer prescription programs. State agencies (Texas Health and Human Services Commission, Minnesota Department of Administration), county health departments (Seminole County, Florida), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance) are the primary issuing bodies, with a mix of competitive IFB and RFP notices and exploratory RFI mechanisms. The work being solicited ranges from annual supply contracts for specific pharmaceutical products through authorized wholesalers to strategic initiatives redesigning how state pharmacy benefit programs source and fulfill prescriptions outside traditional pharmacy benefit manager and group purchasing organization channels.

Recent opportunities span Texas, Minnesota, and Florida. The Minnesota Multistate Cooperative Purchasing Alliance posted an RFP on January 20, 2026 (due March 26, 2026) seeking multiple generic pharmaceutical and OTC product vendors for distribution across state and local government facilities, with pricing weighted at 75 percent of the evaluation and products required available by May 15, 2026 with a two-year initial term. Seminole County, Florida released IFB 60459723LAS on June 30, 2026 (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, on a fixed-fee basis with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 as a market-intelligence gathering mechanism to understand vendor capacity for direct-to-manufacturer prescription programs outside existing PBM and GPO arrangements, with no formal award timeline or budget disclosed at the information-gathering phase.